Key result
Neutrophil elastase inhibitors show potential for abbreviating various types of ischemia-reperfusion injury, though the balance of NE and its inhibitors requires further research.
Why the study?
Although neutrophil elastase is released abundantly in ischemia-reperfusion injury, the intricate relationship between neutrophil elastase and ischemia-reperfusion injury remains unclear.
This review highlights the potential of neutrophil elastase inhibitors as a therapeutic target for mitigating ischemia-reperfusion injury, such as in myocardial infarction.
Should not yet change practice in myocardial infarction; leaves open whether neutrophil elastase inhibition reduces ischemia-reperfusion injury.
Neutrophil elastase (NE), a major protease in neutrophils, is important in promoting inflammation and multiple pathological processes. While NE is released abundantly in ischemiareperfusion (I/R) injury, the intricate relationship between NE and I/R injury remains unclear. We examine several aspects of how NE is involved in I/R injury. We also discuss the possibility of NE inhibitors used for abbreviating various types of I/R injury, such as myocardial infarction, based on preclinical research and clinical trials. Furthermore, we highlight the key question, the balance of NE and NE inhibitors, and propose new research directions. This review is useful for understanding the intrinsic interplay between NE and I/R injury-related diseases and expects to facilitate the development of effective NE inhibitors applied for I/R injury.
No takes yet. Share an insight, caveat, or question.
Wei Zuo (2025) conducted a review in Ischemia-reperfusion (I/R) injury. Neutrophil elastase (NE) inhibitors was evaluated. Neutrophil elastase inhibitors show potential for abbreviating various types of ischemia-reperfusion injury, though the balance of NE and its inhibitors requires further research.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: